Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5

Nephrology Dialysis Transplantation

Volumn 27, Issue 12, 2012, Pages 4361-4368

  Sinha, Manish D ^a   Turner, Charles ^b   Dalton, R N ^b   Rasmussen, Pernille ^a   Waller, Simon ^a   Booth, Caroline J ^a   Goldsmith, David J ^c  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

children; mineral bone disease; phosphate control

Indexed keywords

COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; STAGING; VITAMIN BLOOD LEVEL;

CHILD; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY; MALE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84870482514     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs109     Document Type: Article

References (31)

1. Greenhill C. Risk factors: levels of FGF23 predict outcomes in advanced CKD. Nat Rev Nephrol 2011; 7: 606
2. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
3. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
4. Isakova T, Gutierrez O, Shah A et al. Post prandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19: 615-623
5. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff Vet al. The parathyroid is a target organ for fibroblast growth factor-23 in rats. J Clin Invest 2007; 117: 4003-4008
6. Perwad F, Zhang MYH, Tenenhouse HS et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583
7. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
8. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966
9. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
10. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517
11. Srivaths PR, Goldstein SL, Silverstein DM et al. Elevated FGF23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011; 26: 945-951
12. van Husen M, Fischer A-K, Lehnhardt A et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78: 200-206;
13. Bacchetta J, Dubourg L, Harambat J et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010; 95: 1741-1748
14. Bacchetta J, Ranchin B, Dubourg L et al. FGF23 and paediatric transplantation: a single-centre French experience. Nephrol Dial Transplant 2011; 26: 3421-3422
15. Siomou E, Challa A, Printza N et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol 2011; 26: 1105-1114
16. Sinha MD, Tibby SM, Rasmussen P et al. Blood pressure control and left ventricular mass in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 543-551
17. Schwartz GJ, Haycock GB, Edelmann CM, Jr et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263
18. Hogg RJ, Furth S, Lemley KV. National kidney foundation's kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 11: 1416-1421
19. Dalton RN, Turner C. Development of a reference MS/MS method for plasma creatinine. Clin Chim Acta 2010; 411: 904-905
20. Vickery S, Stevens PE, Dalton RN et al. Does the ID-MS traceable MDRD equation work and is it suitable for use with compensated Jaffe and enzymatic creatinine assays?. Nephrol Dial Transplant 2006; 21: 2439-2445
21. Booth C, Turner C, Dalton RN. Estimated glomerular filtration rate (eGFR) in children. Pediatr Nephrol 2007; 22: 1543. 534(P
22. Ito N, Fukumoto S, Takeuchi Y et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005; 23: 435-440
23. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960
24. Casetta B, Jans I, Billen J et al. Development of a method for the quantification of 1alpha,25(OH)2vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization. Eur J Mass Spectrom (Chichester, Eng) 2009; 16: 81-89
25. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
26. Donate-Correa J, Mora-Fernández C, Martínez-Sanz R et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol 2011; doi.10.1016/j.ijcard.2011.08.850
27. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
28. Dalal M, Sun K, Cappola AR et al. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011; 165: 797-803
29. Taylor EN, Rimm EB, Stampfer MJ et al. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011; 161: 956-962
30. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435
31. Wesseling-Perry K. FGF23: is it ready for prime time?. Clin Chem 2011; 57: 1476-1477